A detailed history of Uniplan Investment Counsel, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Uniplan Investment Counsel, Inc. holds 50,439 shares of ABBV stock, worth $8.86 Million. This represents 0.92% of its overall portfolio holdings.

Number of Shares
50,439
Previous 53,511 5.74%
Holding current value
$8.86 Million
Previous $9.18 Million 8.52%
% of portfolio
0.92%
Previous 0.83%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $503,316 - $612,341
-3,072 Reduced 5.74%
50,439 $9.96 Million
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $147,669 - $172,445
-954 Reduced 1.75%
53,511 $9.18 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $1.42 Million - $1.62 Million
-8,875 Reduced 14.01%
54,465 $9.92 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $613,971 - $691,476
-4,462 Reduced 6.58%
63,340 $9.8 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $205,523 - $255,759
-1,551 Reduced 2.24%
67,802 $9.13 Million
Q1 2023

May 15, 2023

SELL
$144.61 - $166.54 $32,537 - $37,471
-225 Reduced 0.32%
69,353 $11.1 Million
Q4 2022

Feb 14, 2023

BUY
$138.31 - $165.87 $788,228 - $945,293
5,699 Added 8.92%
69,578 $11.2 Million
Q3 2022

Nov 14, 2022

BUY
$134.21 - $153.93 $203,059 - $232,896
1,513 Added 2.43%
63,879 $8.57 Million
Q2 2022

Aug 15, 2022

BUY
$137.62 - $174.96 $661,539 - $841,032
4,807 Added 8.35%
62,366 $9.55 Million
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $65,858 - $81,711
-499 Reduced 0.86%
57,559 $9.33 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $268,360 - $339,553
-2,498 Reduced 4.13%
58,058 $7.86 Million
Q3 2021

Nov 15, 2021

SELL
$106.4 - $120.78 $32,026 - $36,354
-301 Reduced 0.49%
60,556 $6.53 Million
Q2 2021

Aug 13, 2021

SELL
$105.21 - $117.21 $428,835 - $477,747
-4,076 Reduced 6.28%
60,857 $6.85 Million
Q1 2021

May 14, 2021

SELL
$102.3 - $112.62 $525,310 - $578,303
-5,135 Reduced 7.33%
64,933 $7.03 Million
Q4 2020

Feb 12, 2021

SELL
$80.49 - $108.67 $719,741 - $971,727
-8,942 Reduced 11.32%
70,068 $7.51 Million
Q3 2020

Nov 13, 2020

SELL
$85.91 - $100.83 $460,219 - $540,146
-5,357 Reduced 6.35%
79,010 $6.92 Million
Q2 2020

Aug 14, 2020

SELL
$73.37 - $98.18 $826,953 - $1.11 Million
-11,271 Reduced 11.79%
84,367 $8.28 Million
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $398,803 - $604,635
6,183 Added 6.91%
95,638 $7.29 Million
Q4 2019

Feb 14, 2020

SELL
$72.13 - $90.25 $432,130 - $540,687
-5,991 Reduced 6.28%
89,455 $7.92 Million
Q3 2019

Nov 14, 2019

BUY
$62.98 - $75.72 $6.01 Million - $7.23 Million
95,446 New
95,446 $7.23 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Uniplan Investment Counsel, Inc. Portfolio

Follow Uniplan Investment Counsel, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Uniplan Investment Counsel, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Uniplan Investment Counsel, Inc. with notifications on news.